Oncosil Medical Ltd · ASX:OSL
Oncosil Medical — Investor Presentation (February 2026)
29 slides from Oncosil Medical's investor presentation, Feb 3, 2026
Slide 1: Capital Raising Presentation
Capital Raising Presentation February 2026 Nigel Lange, CEO & Managing Director ASX Code: OSL
Slide 2: Disclaimer
Disclaimer This Presentation has been prepared by OncoSil Medical Ltd (ASX:OSL) (OncoSil, OSL or the Company) to provide a general overview of the Company. This Presentation and the information contained may require further explanation and/or clarification. Accordingly, this Presentation and the inf
Slide 3: Executive Summary
Executive Summary • OncoSil Medical is commercialising the OncoSil device, an implanted device (brachytherapy) delivering targeted radiation (32P) to pancreatic tumours Commercialising • OncoSil device is now approved for sale in over 34 countries via CE Mark targeted • Commercial ramp-up has commen
Slide 4: Executive Summary (cont.)
Executive Summary (cont.) • Strong commercial momentum and growing hospital adoption across existing markets: Austria, Germany, Greece, Israel, Italy, Portugal, Spain, Turkey, and the UK • Tender finalisations expected to drive significant revenue growth • Finalisation of G-BA tender process to appo
Slide 5: Pancreatic Cancer Treatment Has Seen Limited Guideline Evolution
Pancreatic Cancer Treatment Has Seen Limited Guideline Evolution Reinforcing the significant unmet need for new therapeutic approaches Disease Progression Disease Progression First-Line (Initial Therapy) LAPC Second-Line LAPC Best Supportive Care Gemcitabine + nab-paclitaxel Gemcitabine + nab-paclit
Slide 6: Expanding Commercial Footprint Across Key European Markets
Expanding Commercial Footprint Across Key European Markets Growing number of active implanting centres to drive revenue momentum • 2 hospitals already opened before G-BA trial • 40 new hospitals expected to start by 1H CY27 • Expecting to start recruitment in G-BA trial 1H CY26 Germany Commercially
Slide 7: Germany: Capital-Efficient Phase III with Commercial Momentum
Germany: Capital-Efficient Phase III with Commercial Momentum System-funded clinical evidence generation alongside ongoing commercial use Population ~ 84 million Pancreatic Cancer 22,587 Incidence p.a.1 Locally Advanced 6,776 Pancreatic Cancer p.a. Market Opportunity p.a. $264 million The top 40 Ger
Slide 8: G-BA Market Opportunity
G-BA Market Opportunity 4,400 Est. LAPC patients within G-BA Centres (n=40) 280 Est. LAPC patients to be recruited into G-BA Trial1 4,120 Est. pool of patients potentially able to receive OncoSil outside of trial within G-BA sites (eligible for reimbursement2) $168 million (annually) Serviceable mar
Slide 9: How the G-BA Initiative Accretes Significant Value in OncoSil
How the G-BA Initiative Accretes Significant Value in OncoSil $5.6 million Additional Actual + Potential Intangible Benefits Direct Sales Revenue Over Trial Period1 • Level 1 evidence trial (gold standard for regulators/clinicians) • Positive data provides National Reimbursement in Germany • Incorpo
Slide 10: Expanded Label to Facilitate Percutaneous Administration
Expanded Label to Facilitate Percutaneous Administration Expanding Physician Access and Improving Procedural Economics Preliminary results rom the PANCOSIL Investigator Initiated Study, presented at the CIRSE 2025, demonstrate that CT-guided percutaneous administration of OncoSilTM is safe and feasi
Slide 11: High Resection Rates at Ankara Bilkent City Hospital
High Resection Rates at Ankara Bilkent City Hospital Early real-world experience demonstrates strong tumour response and multidisciplinary execution in pancreatic cancer Largest hospital in Türkiye, with >3,700 beds Among the first centres in Türkiye to adopt the OncoSil device in routine clinic
Slide 12: Manufacturing / Clinical Trial Investment Nears Completion
Manufacturing / Clinical Trial Investment Nears Completion OncoSil Has Invested Significantly into Building Capability and Generating Clinical Evidence to Drive Commercial Adoption and Regulatory Changes Second Manufacturing Facility – Macquarie Park, Sydney Clinical Trial Investment (TRIPP-FFX, PAN
Slide 13: M&A Activity in the Interventional Radiology Space
M&A Activity in the Interventional Radiology Space Significant M&A Activity in IR/Interventional Oncology since 2018 Acquirer Alicon (China) Target [Embolic Bead Business] 13
Slide 14: Upcoming Milestones
Upcoming Milestones Expected commercial catalysts over the next 18 months First commercial dose Completion of recruitment Regulatory submission for supply from Sydney, at TRIPP-FFX and percutaneous application Australia facility Expansion in new markets PANCOSIL trials Commercial (South East Asia) F
Slide 15: Offer Details
Offer Details
Slide 16: Offer Details
Offer Details Equity Raising of $8.0 million via a $6.0 million Placement and $2.0 million Entitlement Offer • OncoSil has announced the launch of an equity raising of approximately A$8.0 million, comprising: o A $3.2 million Tranche 1 Placement of approximately 4.7 million New Shares in accordance
Slide 17: Use of Funds & Timetable
Use of Funds & Timetable Sources (A$m) Timetable Placement $6.0 Trading halt Friday, 30 January 2026 Trading halt lifted and recommence trading on an ex-entitlement basis Tuesday, 3 February 2026 Entitlement Offer $2.0 Record Date for Entitlement Offer 7:00pm Friday, 6 February 2026 Total $8.0 Settl
Slide 18: Appendix
Appendix
Slide 19: How the OncoSil Device Works
How the OncoSil Device Works Video Link 30
Slide 20: Growing Body of Evidence
Growing Body of Evidence 4 clinical studies supporting commercialisation demonstrate efficacy, safety and tolerability in LAPC Unresectable LAPC Unresectable Locally Advanced Pancreatic Cancer (LAPC) Metastatic PDAC or Borderline-Resectable LAPC Study PanCO Study 1 OncoPaC-1 Study 2 Propensity Score
Slide 21: OncoSil plus Standard-of-Care Chemotherapy
OncoSil plus Standard-of-Care Chemotherapy Second Comparative Analysis confirms superiority of OncoSil compared to chemotherapy + SBRT, considered the most-targeted form of EBRT 1 Increases the number of patients who could be eligible Clinically Significant Significantly More Patients for OncoSil by
Slide 22: OncoSil plus Standard-of-Care Chemotherapy
OncoSil plus Standard-of-Care Chemotherapy Landmark analysis supports evidence of transforming prognosis and extending survival Adding OncoSil to chemotherapy led to a high proportion of patients having -52% substantial reductions in their tumour volume (median 51.9%; range +11% Clinically Significa
Slide 23: OncoSil plus Standard-of-Care Chemotherapy
OncoSil plus Standard-of-Care Chemotherapy At least doubling the number achieving surgical resection or downstaging compared to chemotherapy alone1,2 Around 1 in 4 patients (23.8% in PanCO; 28.6% in the More Than Doubled the More Than Doubled the Propensity Score analysis) with unresectable LAPC Num
Slide 24: Key Risks
Key Risks Shareholders should consider the investment in the context of their individual risk profile for speculative investments, investment objectives and individual financial circumstances. Each Shareholder should consult their own stockbroker, solicitor, accountant or other professional adviser
Slide 25: Key Risks (continued)
Key Risks (continued) Intellectual property Securing rights in technology and patents is an integral part of securing potential product value in the outcomes of medical device research and development. Competition in retaining and sustaining protection of technology and the complex nature of technol
Slide 26: International Offer Restrictions
International Offer Restrictions This document does not constitute an offer of new ordinary shares (“New Shares”) of the Company in any jurisdiction in which it would be unlawful. In particular, this document may not be distributed to any person, and the New Shares may not be offered or sold, in any
Slide 27: Summary of the Underwriting Agreement
Summary of the Underwriting Agreement • The Company proposes to make the Entitlement Offer comprising a non-renounceable pro rata entitlement offer to raise up to approximately $2 million (before costs) for the purposes set out in the Investor Presentation. The Company also intends to conduct the Pl
Slide 28: Summary of the Underwriting Agreement (cont.)
Summary of the Underwriting Agreement (cont.) • The Company must conduct the Entitlement Offer in accordance with the Timetable (unless the Underwriter consents in writing to a variation) the Constitution, the ASX Listing Rules, any ASX Waivers, ASIC Modifications, the Corporations Act, and any othe
Slide 29: Nigel Lange
Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com Learn more about OncoSil Medical: • Website • ASX announcements • LinkedIn
OncoSil Medical — Investor Presentation (February 2026) on 6ix